Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Request PDF
Cancers | Free Full-Text | Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
PFS according to the JAVELIN Renal 101 Immuno and JAVELIN Renal 101... | Download Scientific Diagram
Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) - UROONCO Kidney Cancer
Immunotherapy Strategies in Renal Cell Carcinoma - The ASCO Post
First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology | Scientific Reports
ASCO GU 2021: Efficacy and Safety of Avelumab plus Axitinib (A + Ax) Versus Sunitinib (S) in Elderly Patients with Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Updates ASCO GU 2019 - mRCC
Safety and Efficacy Data: The JAVELIN Renal 101 Trial
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101 - ESMO Open
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101 - ESMO Open
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 - Uemura - 2020 - Cancer Science - Wiley Online Library
ASCO 2021: Association Between Neutrophil-to-Eosinophil Ratio (NER) and Efficacy Outcomes in the JAVELIN Renal 101 Study
![PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e664af226abec8594ac677be056e2d38fe37bc93/6-Figure1-1.png "PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar")
PDF] Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma | Semantic Scholar
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
ASCO GU 2020: Depth of Response (DepOR) Analysis and Correlation with Clinical Outcomes from JAVELIN Renal 101
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 - Uemura - 2020 - Cancer Science - Wiley Online Library
Dr. Elias reviews Keynote 426 and JAVELIN Renal 101 clinical trials – UT Southwestern Internal Medicine Journal Watch
ASCO GU 2021: Efficacy and Safety of Avelumab plus Axitinib (A + Ax) Versus Sunitinib (S) in Elderly Patients with Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
Cancers | Free Full-Text | Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
ESMO 2018: JAVELIN Renal 101: A Randomized, Phase 3 Study of Avelumab + Axitinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma
